Drug
Standard Lymphodepletion Regimen
Standard Lymphodepletion Regimen: highest development phase Phase 2/3, developed by Kyverna Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Kyverna Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Standard lymphodepletion regimen NCT06193889 | Phase 2/3 | Myasthenia Gravis |
| Standard lymphodepletion regimen NCT06588491 | Phase 2 | Stiff-Person Syndrome |
Latest
No recent events.
Follow Standard Lymphodepletion Regimen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.